Dopamine receptor 3 might be an essential molecule in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity

BMC Neuroscience

Zhi-hua Ren²  Zhu-gang Wang³  Zhen-yu Lu¹  Ming-min Gu¹  Xiao-lin Wu¹  Fang Wang¹  Jia-wei Lu⁴  Jie Liu⁵  Ying-yin Ni¹  Yan Chen¹ 

[1] Department of Medical Genetics, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;Biopharmaceutical R&D Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou 215126, China;Shanghai Research Centre for Model Organisms, Shanghai 201210, China;Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;Shanghai Institute of Traumatology and Orthopaedics, Rui-Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

关键词: Parkinson’s disease;    1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity;    Dopamine receptor 3;   

Others  :  1140190
DOI  :  10.1186/1471-2202-14-76

 received in 2013-02-05, accepted in 2013-07-15,  发布年份 2013

【 摘 要 】

Background

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces Parkinson’s disease (PD)-like neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) via its oxidized product, 1-methyl-4-phenylpyridinium (MPP+), which is transported by the dopamine (DA) transporter into DA nerve terminals. DA receptor subtype 3 (D3 receptor) participates in neurotransmitter transport, gene regulation in the DA system, physiological accommodation via G protein-coupled superfamily receptors and other physiological processes in the nervous system. This study investigated the possible correlation between D3 receptors and MPTP-induced neurotoxicity. A series of behavioral experiments and histological analyses were conducted in D3 receptor-deficient mice, using an MPTP-induced model of PD.

Results

After the fourth MPTP injection, wild-type animals that received 15 mg/kg per day displayed significant neurotoxin-related bradykinesia. D3 receptor-deficient mice displayed attenuated MPTP-induced locomotor activity changes. Consistent with the behavioral observations, further neurohistological assessment showed that MPTP-induced neuronal damage in the SNpc was reduced in D3 receptor-deficient mice.

Conclusions

Our study indicates that the D3 receptor might be an essential molecule in MPTP-induced PD and provides a new molecular mechanism for MPTP neurotoxicity.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Sian J, Youdim M, Riederer P, Gerlach M: MPTP-induced parkinsonian syndrome, basic neurochemistry. In Molecular, Cellular and Medical Aspects. 6th edition. Edited by Siegel GJ. Philadelphia: Lippincott-Raven; 1999.
• [2]Kopin I: Features of the dopaminergic neurotoxin MPTP. Ann N Y Acad Sci 1992, 648:96-104.
• [3]Riederer P, Laux G: MAO-inhibitors in parkinson’s disease. Exp Neurobiol 2011, 20:1-17.
• [4]Gainetdinov R, Fumagalli F, Jones S, Caron M: Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997, 69:1322-1325.
• [5]Nanhoe-Mahabier W, de Laat K, Visser J, Zijlmans J, de Leeuw F, Bloem B: Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 2009, 10:533-541.
• [6]Okun M: Deep-brain stimulation for parkinson’s disease. N Engl J Med 2012, 367:1529-1538.
• [7]Olanow C, Obeso J, Stocchi F: Drug insight: continuous dopaminergic stimulation in the treatment of parkinson’s disease. Nat Clin Pract Neurol 2006, 7:382-392.
• [8]Hisahara S, Shimohama S: Dopamine receptors and parkinson’s disease. Int J Med Chem 2011, 11:1-16.
• [9]Carlsson A: A paradigmshift in brain research. Science 2001, 294:1021-1024.
• [10]Missale C, Nash S, Robinson S, Jaber M, Caron M: Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-225.
• [11]Kebabian J, Calne D: Multiple receptors for dopamine. Nature 1979, 277:93-96.
• [12]Seeman P: Brain dopamine receptors. Pharmacol Rev 1980, 32:229-313.
• [13]Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S: A targetedmutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996, 93:1945-1949.
• [14]Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, Tonegawa S: Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 1997, 19:837-848.
• [15]Li T, Hou Y, Yan C, Chen T, Zhao Y, Li S: Dopamine D3 receptor knock-out mice display deficits in locomotor sensitization after chronic morphine administration. Neurosci Lett 2010, 485:256-260.
• [16]Carta A, Gerfen C, Steiner H: Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport 2000, 11:2395-2399.
• [17]Schmauss C: A single dose of methamphetamine leads to a long term reversal of the blunted dopamine D1 receptor-mediated neocortical c-fos responses in mice deficient for D2 and D3 receptors. J Biol Chem 2000, 275:38944-38948.
• [18]Glickstein S, Hof P, Schmauss C: Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. Neurosci 2002, 22:5619-5629.
• [19]D’Agata V, Tiralongo A, Castorina A: Parkin expression profile in dopamine d3 receptor knock-out mice brains. Neurochem Res 2009, 34:327-332.
• [20]Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of parkinson’s disease. Nat Protoc 2007, 2:141-151.
• [21]Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y: A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 1985, 50:435-441.
• [22]Exner N, Lutz A, Haass C, Winklhofer K: Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J 2012, 31:3038-3062.
• [23]Klein C, Schlossmacher M: The genetics of parkinson disease: Implications for neurological care. Nat Clin Pract Neurol 2006, 2:136-146.
• [24]Yokoyama H, Kuroiwa H, Kasahara J, Araki T: Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson’s disease. Acta Neurobiol Exp (Wars) 2011, 71:269-280.
• [25]Sagi Y, Weinstock M, Youdim M: Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 2003, 86:290-297.